W. Cuthbert

A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck

M. Spearman, J. Cizeau, J. Entwistle, 2008, Drug design, development and therapy.

A phase I study of VB6-845, an anti-EpCAM fusion protein targeting advanced solid tumours of epithelial origin: preliminary results

G. Macdonald, M. Kowalski, M. Rasamoelisolo, 2008 .

A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck

M. Spearman, J. Entwistle, G. Macdonald, 2009, Medical oncology.

A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck

M. Spearman, J. Cizeau, J. Entwistle, 2008, Drug design, development and therapy.

A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck

M. Spearman, J. Entwistle, G. Macdonald, 2009, Medical oncology.

Chloride secretion inthetrachea ofnullcystic fibrosis mice: theeffects oftransfection withpTriallO-CFTR2

C. Higgins, W. Colledge, D. Gill, 2011 .